Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-108 in Advanced or Metastatic Solid Tumors
NCT07172802Phase 2Recruiting
- Sponsor
- GI Innovation
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of GI-108 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), pancreatic cancer (PC), renal cell carcinoma (RCC), sponsored by GI Innovation. Started Apr 2025; status: recruiting.
02
Drugs
GI-108
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)pancreatic cancer (PC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07172802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172802.